AU2002226030A1 - Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer - Google Patents
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancerInfo
- Publication number
- AU2002226030A1 AU2002226030A1 AU2002226030A AU2603002A AU2002226030A1 AU 2002226030 A1 AU2002226030 A1 AU 2002226030A1 AU 2002226030 A AU2002226030 A AU 2002226030A AU 2603002 A AU2603002 A AU 2603002A AU 2002226030 A1 AU2002226030 A1 AU 2002226030A1
- Authority
- AU
- Australia
- Prior art keywords
- lymphocyte
- cytotoxic
- diagnosis
- cancer
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25102200P | 2000-12-04 | 2000-12-04 | |
| US60/251,022 | 2000-12-04 | ||
| US25682400P | 2000-12-20 | 2000-12-20 | |
| US60/256,824 | 2000-12-20 | ||
| PCT/US2001/047290 WO2002046416A2 (en) | 2000-12-04 | 2001-12-04 | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002226030A1 true AU2002226030A1 (en) | 2002-06-18 |
Family
ID=26941326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002226030A Abandoned AU2002226030A1 (en) | 2000-12-04 | 2001-12-04 | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7083789B2 (en) |
| EP (2) | EP2295575A3 (en) |
| AU (1) | AU2002226030A1 (en) |
| WO (1) | WO2002046416A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7388071B2 (en) * | 2000-02-15 | 2008-06-17 | The Regents Of The University Of California | Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7811828B2 (en) | 2004-01-28 | 2010-10-12 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumuor-associated |
| WO2007030451A2 (en) * | 2005-09-07 | 2007-03-15 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| KR101493773B1 (en) | 2006-10-17 | 2015-03-03 | 온코세라피 사이언스 가부시키가이샤 | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| FR2915393B1 (en) | 2007-04-27 | 2012-12-14 | Vincience | PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING CYTOCHROME C ACTIVE ACTIVATOR |
| FR2915394B1 (en) * | 2007-04-27 | 2012-12-14 | Vincience | PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING PEPTIDES |
| WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| BRPI0913827A2 (en) * | 2008-10-01 | 2020-12-29 | Genentech, Inc | MONOCLONAL ANTIBODY, METHOD TO INHIBIT NOTCH2 ACTIVITY, METHOD TO TREAT A DISEASE, METHOD TO TREAT A MALIGNITY, METHOD TO TREAT A MELANOMA, USES OF AN ANTIBODY AND NRR ANTI-NOTCH2 ANTIBODY |
| EP2172211B1 (en) * | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| BR112014001363B1 (en) | 2011-08-12 | 2021-06-01 | Oncotherapy Science, Inc. | COMPOSITIONS FOR INDUCTION OF A CYTOTOXIC T LYMPHOCYTE (CTL), FOR INDUCTION OF AN ANTIGEN PRESENTING CELL (APC) HAVING CTL INDUCTION CAPACITY, PHARMACEUTICAL COMPOSITION, IN VITRO METHODS FOR INDUCTION OF APC AND CTL OF USES OF PEPTITE |
| WO2013060328A1 (en) | 2011-10-26 | 2013-05-02 | Herlev Hospital | Ikb based immunotherapy |
| WO2014160183A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| CN103739667B (en) * | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | Special tumor antigen peptide of oophoroma and preparation method thereof |
| US10676508B2 (en) | 2015-08-12 | 2020-06-09 | Oncotherapy Science, Inc. | DEPDC1-derived peptide and vaccine containing same |
| TW202023581A (en) * | 2018-08-02 | 2020-07-01 | 日商腫瘤療法 科學股份有限公司 | Cdca1-derived peptide and vaccine containing same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5645994A (en) * | 1990-07-05 | 1997-07-08 | University Of Utah Research Foundation | Method and compositions for identification of species in a sample using type II topoisomerase sequences |
| CA2117303C (en) | 1991-11-29 | 2000-10-17 | Sunil Chada | Anti-cancer immunotherapeutic vector constructs |
| JP3608788B2 (en) | 1992-08-31 | 2005-01-12 | ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ | Isolated nonapeptides derived from the MAGE-3 gene and presented by HLA-A1 and their uses |
| US6051397A (en) * | 1993-11-16 | 2000-04-18 | Max Planck Gesellschaft Zur Forderung Der Wissenschaften | DNA encoding MCK-10, a novel receptor tyrosine kinase |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| FR2765138B1 (en) | 1997-06-27 | 1999-09-17 | Pernod Ricard | PROCESS FOR MANUFACTURING A COMPOSITION FOR USE IN THE PRODUCTION OF PLUGS, COMPOSITION AND PLUG COMPRISING SUCH A COMPOSITION |
-
2001
- 2001-12-04 WO PCT/US2001/047290 patent/WO2002046416A2/en not_active Ceased
- 2001-12-04 US US10/006,177 patent/US7083789B2/en not_active Expired - Fee Related
- 2001-12-04 AU AU2002226030A patent/AU2002226030A1/en not_active Abandoned
- 2001-12-04 EP EP10178439A patent/EP2295575A3/en not_active Withdrawn
- 2001-12-04 EP EP01995455A patent/EP1356048A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2295575A2 (en) | 2011-03-16 |
| WO2002046416A2 (en) | 2002-06-13 |
| EP2295575A3 (en) | 2011-07-06 |
| EP1356048A2 (en) | 2003-10-29 |
| US20030165513A1 (en) | 2003-09-04 |
| WO2002046416A3 (en) | 2003-08-21 |
| US7083789B2 (en) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002226030A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
| AU2001282717A1 (en) | Cancer treatment by combination therapy | |
| IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
| AUPQ893200A0 (en) | Medical residue treatment | |
| AU2001268259A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| ZA200305126B (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
| AU2001269766A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| AU6048201A (en) | Quinazoline derivatives for the treatment of tumours | |
| HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
| AU2002328952A1 (en) | Irinotecan for treatment of cancer | |
| PL354540A1 (en) | Drugs for the treatment of malignant tumours | |
| IL151890A0 (en) | Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
| AU2001280982A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| AU2002246519A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| AU4373499A (en) | Use of drug-loaded nanoparticles for the treatment of cancers | |
| AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
| AU2001263383A1 (en) | Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer | |
| AU2002217866A1 (en) | Geldanamycin derivatives useful for the treatment of cancer | |
| AU2001243349A1 (en) | Methods for the diagnosis and treatment of breast cancer | |
| AU4770800A (en) | Body treatment product | |
| IL151891A0 (en) | Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
| PL357812A1 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | |
| AU2001290518A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| MXPA03006412A (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
| AU2001214116A1 (en) | Novel paclitaxel derivatives for the treatment of cancer |